Optima Capital’s Royalty Pharma RPRX Stock Holding History

Optima Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5	Closed	-$193	–	1054
2025 Q4	$193	Buy	+5	New	+$191	﹤0.01%	1334

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Optima Capital's RPRX Position: Q1 2026 in Review

Optima Capital sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 5 shares — an estimated $193 sold.

Optima Capital first reported a position in RPRX in Q4 2025 and held it in 1 quarter. The position peaked at $193 in Q4 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Optima Capital reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 5 Royalty Pharma shares in Q1 2026, an estimated $193.
Optima Capital first reported a position in Royalty Pharma in Q4 2025 and held it in 1 quarter.
Optima Capital's Royalty Pharma position peaked at $193 in Q4 2025.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.